Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of VX-659 + tezacaftor + ivacaftor in cystic fibrosis patients homozygous for F508del
2017-004133-82Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing VX-659 triple combination with Tezacaftor + ivacaftor active control (2 arms). Primary endpoint: Absolute change in percent predicted forced expiratory volume in 1 second from baseline at Week 4. Started Mar 2018; status: completed.
02
Drugs
bamocaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-004133-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004133-82.